Advancements in cell-free DNA (cfDNA) are enabling less invasive fetal blood group testing, improving transplant monitoring, and opening the door to safer, more targeted transfusion care. Here, Pearl Audon and Gagan Mathur, from the University of California, share insights into this evolving landscape and what it means for laboratory professionals.
cfDNA testing is gaining traction across multiple areas of pathology. What does it offer as a diagnostic tool compared with traditional tissue-based testing?
cfDNA offers a minimally invasive way to obtain molecular information that would traditionally require a tissue biopsy, while also enabling longitudinal disease monitoring.
Tissue biopsy remains the gold standard for diagnosis, grading, staging, and morphologic assessment, but it provides only a single snapshot from one site. By contrast, cfDNA reflects ongoing cellular turnover across the body and can be assessed repeatedly through simple blood draws. This is particularly valuable when tissue is difficult to obtain, unsafe to collect, or insufficient for serial testing. Rather than replacing histopathology, cfDNA should be viewed as a complementary tool that expands the laboratory’s ability to monitor disease biology over time.
In which clinical settings do you see cfDNA having the greatest immediate impact?
The most established applications of cfDNA are in prenatal testing and oncology. Non-invasive prenatal testing is now routine clinical practice, enabling fetal genetic and blood group assessment without procedural risk. In oncology, cfDNA supports tumor genotyping, detection of resistance mutations, and longitudinal monitoring of disease burden, particularly when repeat tissue biopsies are not feasible.
Solid organ transplantation is another rapidly advancing area, where donor-derived cfDNA is being used to detect allograft injury and guide clinical decision-making. In this setting, cfDNA has shown strong negative predictive value for rejection, potentially reducing the need for invasive biopsies in selected patients.
An emerging but under-recognized area is transfusion medicine, where cfDNA may help characterize immune and inflammatory responses to transfusion and support management of complex immunologic conditions, although these applications are still evolving.
What are the main technical and interpretive challenges laboratories face when implementing cfDNA-based assays?
The challenges span preanalytic, analytic, and interpretive domains. cfDNA is present at low concentrations and is highly fragmented, making results highly sensitive to specimen collection, handling, and processing. Even small workflow variations can significantly affect assay performance.
Most assays rely on highly sensitive technologies, such as next-generation sequencing or digital PCR, to detect small amounts of clinically relevant DNA within a large background of normal DNA.
Interpretation is often the greatest challenge. cfDNA represents a heterogeneous mixture derived from multiple tissues, and results can be influenced by factors including inflammation, pregnancy, transplantation, recent transfusion, or age-related clonal hematopoiesis. As a result, accurate interpretation requires careful integration of cfDNA findings with clinical context and other laboratory data.
How do issues such as sensitivity, specificity, and standardization affect the reliability of cfDNA results in routine practice?
cfDNA testing depends heavily on clinical context, disease burden, and assay design. Highly sensitive assays can detect very low levels of cfDNA, although not all detected signals are clinically meaningful, while less sensitive methods may miss early or low-volume disease.
In transplantation, for example, donor-derived cfDNA shows good sensitivity for detecting allograft injury and a strong negative predictive value for rejection. However, specificity remains limited because elevated cfDNA levels can reflect multiple forms of tissue injury.
Standardization also remains a major challenge, as platforms differ in targets, methodologies, and reporting thresholds. As a result, cfDNA findings are most reliable when interpreted longitudinally and within the context of the specific assay used, rather than as isolated measurements.
What are the key considerations for laboratories looking to integrate cfDNA testing into existing workflows?
Successful integration of cfDNA testing requires clearly defined clinical use cases, strong preanalytic controls, and appropriate analytical and informatics infrastructure. Laboratories must standardize specimen collection and processing, select platforms suited to the intended clinical application, and implement robust bioinformatics pipelines for interpretation.
Equally important is ensuring results are reported in a clinically meaningful way and integrated into existing diagnostic workflows. cfDNA testing is most effective when used to answer specific clinical questions that will directly influence patient management, rather than as a broad screening tool. Education for both clinicians and laboratory staff is also essential to support appropriate test utilization and interpretation.
How does cfDNA testing change the role of the pathologist in diagnosis and disease monitoring?
cfDNA is expanding the role of the pathologist from making primarily static diagnoses to interpreting longitudinal, biology-driven data. Pathologists increasingly act as integrators, combining cfDNA trends with clinical findings, histopathology, and other laboratory results to guide patient management.
This is particularly relevant in oncology and transplantation, and is emerging in transfusion medicine, where cfDNA may help monitor dynamic biologic processes rather than isolated abnormalities at a single time point. As the field evolves, the pathologist’s role is shifting from simply reporting results to providing broader interpretive guidance within the clinical context.
Are there particular areas where cfDNA is currently over- or under-utilized in clinical diagnostics?
There is potential for overutilization when cfDNA testing is ordered without a clear clinical indication or when results are interpreted without adequate clinical context, particularly in oncology. Conversely, cfDNA remains underutilized in areas such as transplant surveillance and transfusion medicine, where supporting evidence is growing but clinical adoption remains inconsistent.
In these settings, cfDNA could help reduce invasive procedures and provide insight into ongoing biologic responses, although broader implementation will require stronger outcomes data and clearer clinical pathways. Adoption is increasingly supported by emerging practice recommendations, but real-world integration remains variable.
Looking ahead, what developments are needed for cfDNA to reach its full potential in pathology, and how might this shape future laboratory practice?
Advancing cfDNA toward its full clinical potential will require improved standardization, greater specificity, and stronger integration with other data sources. Emerging approaches such as tissue-of-origin analysis, methylation profiling, and multi-analyte testing are likely to improve interpretability and clinical relevance.
Equally important will be the development of validated clinical thresholds and harmonized reporting frameworks. As these advances mature, cfDNA is expected to become part of integrated, longitudinal diagnostic models that combine molecular, clinical, and temporal data. Laboratories with expertise in interpreting these complex signals will play a central role in the future of precision diagnostics.
Newsletters
Receive the latest pathologist news, personalities, education, and career development – weekly to your inbox.
